Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

Pfizer's recent acquisition target, Metsera, has released promising mid-stage trial data for its lead obesity drug candidate, MET-097i, a GLP-1 treatment aiming for convenient once-a-month dosing. The drug demonstrated up to 14.1% average weight loss and strong tolerability, positioning it as a potential competitor to market leaders like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, with analysts projecting over $5 billion in peak annual sales. This development, ahead of planned Phase 3 studies, validates Pfizer's up to $7.3 billion investment and signals increased competition in the lucrative obesity drug market.

Analysis

Pfizer's acquisition of Metsera is being rapidly de-risked following the release of promising mid-stage trial data for its lead obesity drug, MET-097i. This GLP-1 candidate demonstrated up to 14.1% average weight loss after 28 weeks, a result analysts at JPMorgan deemed "solid" and in line with Eli Lilly's Zepbound profile. Critically, MET-097i exhibits two potential key differentiators: a strong tolerability profile, evidenced by a low 2.9% discontinuation rate and modest gastrointestinal side effects in trials, and the potential for a convenient once-a-month dosing regimen, a significant advantage over the weekly injections from market leaders Novo Nordisk and Eli Lilly. While direct efficacy comparisons await late-stage, head-to-head trials, the early data validates Pfizer's up to $7.3 billion investment and supports analyst projections, such as Leerink Partners' estimate of over $5 billion in peak annual sales from Metsera's pipeline. This development signals intensifying future competition in the lucrative obesity market, with MET-097i emerging as a credible future challenger poised to capture market share.

Key Decisions for Investors

• For Pfizer (PFE) investors, the positive MET-097i data provides a significant catalyst for its pipeline, and the initiation of Phase 3 trials later this year should be monitored as the next key milestone toward realizing the drug's multi-billion dollar sales potential.
• Investors in Eli Lilly (LLY) and Novo Nordisk (NVO) should consider the rising competitive threat from MET-097i, which could erode long-term market share if its convenient monthly dosing and favorable tolerability are confirmed in late-stage trials.
• The most critical upcoming data point is the initial weight loss results from the VESPER-3 monthly dosing study, expected by early 2026, which will be the primary determinant of the drug's competitive positioning against incumbent weekly treatments.